biotechnology

Adam's Take

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

By Adam Feuerstein

FDA
Adam's Take

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

By Adam Feuerstein

lung caner jan 20
Biotech

Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO

By Jonathan Saltzman — Boston Globe

Adam's Take

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

By Adam Feuerstein

IMMUNOTHERAPY lab
Biotech

With a clinical hold, off-the-shelf CAR-T hits a new safety concern

By Damian Garde

govt. money
Biotech

Venter Institute, Yumanity, and other biopharma companies among recipients of PPP loans

By Kate Sheridan

mammograms_CA
Biotech

Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial

By Adam Feuerstein

purple lungs ct
Biotech

Bellus Health suffers setback with clinical trial failure of chronic cough drug

By Adam Feuerstein

MODERNA - Norwood facility
Health

Trial of Moderna Covid-19 vaccine delayed, investigators say, but July start still possible

By Damian Garde

Covid-19 vaccine testing ethics
Biotech

Inovio claims positive results on Covid-19 vaccine but critical data are missing

By Damian Garde and Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the third quarter: 14 stock-moving events to watch

By Adam Feuerstein

Remdesivir vials in bags
Biotech

How Gilead’s remdesivir price could come back to haunt the drug industry

By Damian Garde

Liver illustration
Biotech

FDA rejects Intercept Pharma’s drug for NASH

By Adam Feuerstein

Colorful DNA molecule
Biotech

Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments

By Matthew Herper

Biotech

Zogenix wins approval for new drug to treat rare type of childhood epilepsy

By Adam Feuerstein

Regeneron HQ
Pharmalot

Federal prosecutors allege Regeneron used a charity to pay kickbacks to Medicare patients

By Ed Silverman

Biotech

Yumanity Therapeutics, Merck strike deal aimed at developing new medicines for neurodegenerative disease

By Adam Feuerstein

Fatty Liver
Biotech

As approval decision nears, fate of Intercept’s NASH drug clouded by murky FDA review delays

By Adam Feuerstein

Unicorn Stocks
Biotech

Sana Biotechnology, the secretive startup, lays (some) cards on the table

By Kate Sheridan

Blood sugar monitor - finger stick
Biotech

A Chinese drug maker scores a big clinical trial win with a novel diabetes therapy

By Jonathan Chan

Man coughing
Biotech

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

By Adam Feuerstein

Biotech

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

By Adam Feuerstein

Liver fibrosis IC
Health

CAR-T cells, better known as cancer drugs, show promise against aging in lab mice

By Sharon Begley

Breast Cancer Cell - pink

Eli Lilly gets an edge against Pfizer in adjuvant breast cancer

By Matthew Herper

IV Drip
Biotech

Momenta Pharma drug improves symptoms in patients with myasthenia gravis

By Adam Feuerstein

stat_spacerace
Biotech

What’s at stake for industry in the pharmaceutical Space Race for a Covid-19 vaccine

By Damian Garde

Sinovac Biotech facilities in Beijing
Health

Sinovac says early data show its Covid-19 vaccine generated immune responses

By Adam Feuerstein

ASH 19 - Fluorescent osteoblast cells
Biotech

As efficacy of Constellation’s blood cancer drug wanes, the debate over its future ratchets higher

By Adam Feuerstein

Biotech

Agios drug demonstrates strong response in patients with inherited blood disorder

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy